Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Receivables (2024 - 2025)

Historic Change in Receivables for Madrigal Pharmaceuticals (MDGL) over the last 5 years, with Q3 2025 value amounting to $34.1 million.

  • Madrigal Pharmaceuticals' Change in Receivables rose 4451.71% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 17187.74%. This contributed to the annual value of $53.8 million for FY2024, which is N/A changed from last year.
  • Madrigal Pharmaceuticals' Change in Receivables amounted to $34.1 million in Q3 2025, which was up 4451.71% from $17.8 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Change in Receivables peaked at $34.1 million during Q3 2025, and registered a low of $6.9 million during Q2 2024.